ADVERTISEMENT

Psychedelics News

Mydecine

Industry

25 Apr 2023

Mydecine Reports Positive Preclinical Results on MYCO-006 Short-Acting MDMA Analogues

Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with...

By Microdose NewsDesk

Finance

14 Dec 2022

Mydecine Closes Sale of Mindleap for $3.6 million

Mydecine as closed a sale of their app, with PanGenomic acquiring all of Mindleap's outstanding shares for a purchase price of C$3,600,000...

By Microdose NewsDesk

Don’t Miss

26 Sep 2022

News You Might Have Missed: Sep 26th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Finance

20 Sep 2022

Roth Capital Suspends Rating on Mydecine

As reported recently, Mydecine has been going through some volatile moments as of late....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

19 Jul 2022

Mydecine Files Patent Application For Short-Acting MDMA

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs...

By Microdose NewsDesk

Don’t Miss

28 Jun 2022

News You Might Have Missed: June 28th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

ADVERTISEMENT

Follow us on social

Latest News

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads